Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $20.2857.

ENTA has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Wall Street Zen cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals in a research note on Thursday, March 26th. They set a “buy” rating and a $20.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $14.06 on Wednesday. The firm has a market cap of $408.86 million, a P/E ratio of -5.43 and a beta of 0.97. The business’s 50 day moving average price is $13.32 and its 200-day moving average price is $13.65. Enanta Pharmaceuticals has a fifty-two week low of $6.43 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $17.16 million during the quarter, compared to analysts’ expectations of $17.03 million. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%. As a group, equities analysts predict that Enanta Pharmaceuticals will post -1.79 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $32,000. Seven Fleet Capital Management LP purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $36,000. Strs Ohio purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Enanta Pharmaceuticals by 333.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 2,758 shares during the last quarter. Finally, Quarry LP purchased a new position in Enanta Pharmaceuticals during the third quarter valued at $81,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.